MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia

Patients with Waldenstrom's macroglobulinemia without mutations in MYD88 tend to have a shorter median survival and a lower probability of response to ibrutinib than do those with MYD88 mutations.